Collaborations & Alliances

Baxalta, Symphogen in Strategic Immuno-oncology Alliance

Aims to advance novel therapeutics against six checkpoint targets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta and Symphogen have entered a broad strategic immuno-oncology collaboration aimed at advancing novel therapeutics against six checkpoint targets. Based on successful completion of Phase I trials, expected to enter clinical studies in 2017, Baxalta will have exclusive option rights to complete late-stage development and worldwide commercialization. Symphogen will receive an upfront payment of $175 million in exchange for the exclusive option rights for six checkpoint therapies. Symphogen w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters